Trial Profile
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP SINGLE-DOSE STUDY TO ESTIMATE THE EFFECT OF AGE ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF INTRAVENOUS RIVIPANSEL (PF-06460031)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2020
Price :
$35
*
At a glance
- Drugs Rivipansel (Primary)
- Indications Haematological malignancies; Sickle cell anaemia; Vaso-occlusive crisis
- Focus Pharmacokinetics
- Sponsors GlycoMimetics; Pfizer
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 06 Apr 2017 Status changed from recruiting to completed.
- 13 Mar 2017 Planned End Date changed from 1 Apr 2017 to 16 Mar 2017.